BR0111142A - Utilização de derivados de biguanida ou de seus sais farmaceuticamente aceitáveis - Google Patents

Utilização de derivados de biguanida ou de seus sais farmaceuticamente aceitáveis

Info

Publication number
BR0111142A
BR0111142A BR0111142-6A BR0111142A BR0111142A BR 0111142 A BR0111142 A BR 0111142A BR 0111142 A BR0111142 A BR 0111142A BR 0111142 A BR0111142 A BR 0111142A
Authority
BR
Brazil
Prior art keywords
group
pharmaceutically acceptable
acceptable salts
biguanide derivatives
medicament
Prior art date
Application number
BR0111142-6A
Other languages
English (en)
Other versions
BRPI0111142C1 (pt
BRPI0111142B8 (pt
BRPI0111142B1 (pt
Inventor
Jean-Pierre Potier
Nobumichi-Andre Sasaki
Achib Maria Conception I
Gisele Franck
Claude Thal
Joanna Bakala
Original Assignee
Ct Nat De La Recheche Scient C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8850685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0111142(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Nat De La Recheche Scient C filed Critical Ct Nat De La Recheche Scient C
Publication of BR0111142A publication Critical patent/BR0111142A/pt
Publication of BRPI0111142B1 publication Critical patent/BRPI0111142B1/pt
Publication of BRPI0111142B8 publication Critical patent/BRPI0111142B8/pt
Publication of BRPI0111142C1 publication Critical patent/BRPI0111142C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

"UTILIZAçãO DE DERIVADOS DE BIGUANIDA OU DE SEUS SAIS FARMACEUTICAMENTE ACEITáVEIS". A presente invenção refere-se à utilização de derivados de biguanida de fórmula geral (I) na qual: os grupos R1 e R2 representam independentemente um do outro, um átomo de hidrogênio, um grupo alquila C~ 1~-C~ 7~, um grupo cicloalquila, um heterociclo, um grupo alquenila C~ 2~-C~ 7~, um grupo arila, um grupo aralquila, um grupo arilóxialquila ou um grupo heteroarila ou R1 e R2 juntos representam um grupo alquileno C~ 2~-C~ 7~ podendo conter um ou vários heteroátomos e o grupo R3 representa uma amina primária, secundária ou terciária ou seus sais farmaceuticamente aceitáveis para a fabricação de um medicamento com um efeito cicatrizante, o referido medicamento estando em forma farmacêutica de uso tópico.
BRPI0111142A 2000-05-26 2001-05-23 utilização de derivados de biguanida ou sais farmaceuticamente aceitáveis dos mesmos para fabricação de medicamento tendo um efeito cicatrizante BRPI0111142C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR00/06798 2000-05-26
FR0006798A FR2809310B1 (fr) 2000-05-26 2000-05-26 Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
PCT/FR2001/001598 WO2001091696A2 (fr) 2000-05-26 2001-05-23 Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant

Publications (4)

Publication Number Publication Date
BR0111142A true BR0111142A (pt) 2003-04-08
BRPI0111142B1 BRPI0111142B1 (pt) 2017-10-24
BRPI0111142B8 BRPI0111142B8 (pt) 2018-05-02
BRPI0111142C1 BRPI0111142C1 (pt) 2021-05-25

Family

ID=8850685

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0111142A BRPI0111142C1 (pt) 2000-05-26 2001-05-23 utilização de derivados de biguanida ou sais farmaceuticamente aceitáveis dos mesmos para fabricação de medicamento tendo um efeito cicatrizante

Country Status (25)

Country Link
US (1) US7199159B2 (pt)
EP (1) EP1283708B1 (pt)
JP (1) JP4987209B2 (pt)
KR (1) KR20030029050A (pt)
CN (1) CN100420439C (pt)
AR (1) AR032617A1 (pt)
AT (1) ATE300942T1 (pt)
AU (2) AU2001264011B2 (pt)
BG (1) BG65847B1 (pt)
BR (1) BRPI0111142C1 (pt)
CA (1) CA2410025C (pt)
DE (1) DE60112431T2 (pt)
DK (1) DK1283708T3 (pt)
EC (1) ECSP024359A (pt)
EE (1) EE05393B1 (pt)
ES (1) ES2244625T3 (pt)
FR (1) FR2809310B1 (pt)
HU (1) HU229205B1 (pt)
MX (1) MXPA02011622A (pt)
MY (1) MY137468A (pt)
NO (1) NO20025635L (pt)
PT (1) PT1283708E (pt)
SK (1) SK287249B6 (pt)
UA (1) UA76415C2 (pt)
WO (1) WO2001091696A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2858232B1 (fr) * 2003-07-29 2006-03-03 Pierre Potier Utilisation d'un derive de biguanide pour proteger la peau des radiations uvb
DE102004022645A1 (de) * 2004-05-07 2005-12-15 Resorba Wundversorgung Gmbh & Co. Kg Bioresorbierbares Material auf Kollagen-Basis
JP4877456B2 (ja) * 2005-04-14 2012-02-15 株式会社 メドレックス ビグアナイド系薬剤を含有するゼリー製剤
EP2109447B1 (en) 2007-01-29 2015-06-10 HanAll Biopharma Co., Ltd. N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
US20100055142A1 (en) * 2008-08-28 2010-03-04 Tyco Healthcare Group Lp Carrier Neutralization/Modification in Antimicrobial Compositions, Articles and Methods
WO2011083999A2 (ko) 2010-01-06 2011-07-14 한올바이오파마주식회사 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
GB2510712A (en) 2011-07-22 2014-08-13 Karel Paul Bouter Nutritional product comprising a biguanide
KR101424667B1 (ko) * 2011-08-08 2014-08-04 한올바이오파마주식회사 Ｎ1-고리아민-ｎ2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
ES2869423T3 (es) * 2011-08-08 2021-10-25 Immunomet Therapeutics Inc Derivados de fenilbiguanida N1-amina cíclica-N5-sustituidos y composición farmacéutica que comprende los mismos
US9321742B2 (en) 2011-08-08 2016-04-26 Immunomet Therapeutics Inc. N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
WO2015160220A1 (en) * 2014-04-17 2015-10-22 Hanall Biopharma Co., Ltd. Guanidine compounds and use thereof
CN104262205B (zh) * 2014-09-02 2017-04-12 浙江工业大学 N‑芳基双胍氢碘酸盐类化合物及其制备方法和应用
KR102216701B1 (ko) 2014-11-20 2021-02-18 이뮤노메트테라퓨틱스 인코포레이티드 바이구아나이드 화합물 및 이의 용도
FR3035787B1 (fr) 2015-05-07 2018-08-24 L'oreal Procede de traitement des matieres keratiniques a partir de derives de c-glycosides amides, acides ou ester, et la composition cosmetique les contenant
FR3053892A1 (fr) 2016-07-12 2018-01-19 Urgo Recherche Innovation Et Developpement Pansement permettant la liberation controlee et prolongee de la metformine
CN106822075A (zh) * 2017-03-31 2017-06-13 浙江萧山医院 二甲双胍在促进伤口愈合中的应用
FR3068974B1 (fr) 2017-07-12 2019-08-02 Urgo Recherche Innovation Et Developpement Pansement permettant la liberation controlee et prolongee d'actif
FR3088542B1 (fr) 2018-11-21 2021-03-19 Waterdiam France Sas Composition cicatrisante comprenant une eau électrolysée
CN110179776B (zh) * 2019-05-31 2022-09-06 宁夏医科大学 二甲双胍的新用途与二甲双胍组合物及组合物的制备方法和应用
CN112494469A (zh) * 2020-07-30 2021-03-16 吴学雷 二甲双胍在制备预防和/或治疗瘢痕的药物中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB852584A (en) 1956-05-31 1960-10-26 Us Vitamin Corp Biguanide compositions
US2961377A (en) 1957-08-05 1960-11-22 Us Vitamin Pharm Corp Oral anti-diabetic compositions and methods
US3098008A (en) * 1960-10-05 1963-07-16 Us Vitamin Pharm Corp Method for treatment of dermatological disorders
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3468898A (en) 1966-05-26 1969-09-23 Sterling Drug Inc Bridged bis-biguanides and bis-guanidines
US3996232A (en) * 1970-11-23 1976-12-07 William H. Rorer, Inc. 1,5-Disubstituted biguanides
GB1351025A (en) 1971-08-20 1974-04-24 Aron Md Samuel J Oxadiazol-5-yl biguanide derivatives method for their preparation and pharmaceutical compositions containing them
US3852353A (en) 1972-12-12 1974-12-03 C Heaphy Oral hypoglycemic aminophenylsulfonyl-hydrocarbylbiguanides
US3929999A (en) 1972-12-12 1975-12-30 Clifford John Heaphy Oral hypoglycemic method
DE2401450A1 (de) * 1973-01-16 1974-07-18 John James Voorhees Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen
US4211770A (en) * 1973-01-16 1980-07-08 The Upjohn Company Treatment of psoriasis intralesionally with N6 -2'-O-dibutyryl cyclic AMP
CH602612A5 (pt) 1974-10-11 1978-07-31 Hoffmann La Roche
FR2320735A1 (fr) * 1975-08-12 1977-03-11 Dabis Georges Composition anti-cellulite
US4163800A (en) * 1977-08-17 1979-08-07 The Procter & Gamble Company Topical composition and treatment of skin lesions therewith
NZ207147A (en) 1983-02-28 1987-08-31 Johnson & Johnson Prod Inc Adhesive bandage containing medicinal substance: pad and base prepared from bulky, non-woven material
FR2552305B1 (fr) * 1983-09-22 1985-12-20 Salkin Andre Composition a pouvoir bactericide eleve contenant un biguanide et une pyrimidine
FR2585572B3 (fr) 1985-07-31 1987-12-31 Hugelin Andre Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse
FR2611500B1 (fr) * 1987-03-06 1990-05-04 Lipha Emploi de derives du biguanide dans la preparation de medicaments
AU1834188A (en) 1987-06-29 1989-01-05 Kendall Company, The Novel medicated dressings
US5246708A (en) 1987-10-28 1993-09-21 Pro-Neuron, Inc. Methods for promoting wound healing with deoxyribonucleosides
SU1560212A1 (ru) 1988-11-10 1990-04-30 Киевский Медицинский Институт Им.Акад.А.А.Богомольца Способ лечени сифилиса
IT1241994B (it) 1990-08-30 1994-02-02 Idi Farmaceutici Composizione farmaceutica ad effetto cicatrizzante.
IL97771A (en) * 1991-04-04 1996-12-05 Sion Narrow Weaving Dry polymeric material having antimicrobial activity
IT1249711B (it) * 1991-09-30 1995-03-09 Boniscontro E Gazzone S R L Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici,indicate nella terapia dei tessuti superficiali.
IT1256111B (it) * 1992-11-23 1995-11-28 Lifegroup Spa Sali dell'acido traumatico ad attivita' cicatrizzante ed antibatterica
JP3493692B2 (ja) 1993-09-09 2004-02-03 三菱マテリアル株式会社 ビスビグアナイド系化合物およびそれを含む殺菌剤
DE19503336C2 (de) * 1995-02-02 1998-07-30 Lohmann Therapie Syst Lts Arzneiform zur Abgabe von Wirkstoffen an Wunden, Verfahren zu ihrer Herstellung und ihre Verwendung
US5747527A (en) * 1995-06-06 1998-05-05 Shaman Pharmaceuticals, Inc. Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
US5668084A (en) 1995-08-01 1997-09-16 Zeneca Inc. Polyhexamethylene biguanide and surfactant composition and method for preventing waterline residue
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
US5837255A (en) * 1996-12-10 1998-11-17 Shaman Pharmaceuticals, Inc. Method of reducing blood glucose by administering Harunganin or Vismin
US5741926A (en) * 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
US5811078A (en) * 1997-03-14 1998-09-22 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions therewith
JP3054758B2 (ja) * 1997-03-27 2000-06-19 小林製薬株式会社 外傷用組成物
CN1197643A (zh) * 1997-04-30 1998-11-04 谢瑞钢 一种创伤油膏
JP4278863B2 (ja) * 1997-12-08 2009-06-17 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法
PL341309A1 (en) * 1997-12-22 2001-04-09 Euro Celtique Method of preventing overdosage of opioidic preparations
BR9912395A (pt) * 1998-07-24 2001-10-16 Seo Hong Yoo Preparação de formas de dosagem de solução clara aquosa com ácidos biliares
WO2000033829A1 (de) 1998-12-05 2000-06-15 Fresenius Kabi Deutschland Gmbh Verwendung von poly (hexamethylen) biguanid zur herstellung eines mittels zur förderung der heilung von infektionsfreien wunden
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
AU3982601A (en) * 2000-02-23 2001-09-03 Orentreich Foundation For The Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
ATE266409T1 (de) * 2000-04-13 2004-05-15 Pfizer Prod Inc Synergistische wirkung von glyburide und milrinone

Also Published As

Publication number Publication date
EE200200657A (et) 2004-06-15
FR2809310A1 (fr) 2001-11-30
CA2410025C (fr) 2011-09-06
PL359063A1 (en) 2004-08-23
DK1283708T3 (da) 2005-12-27
BRPI0111142C1 (pt) 2021-05-25
JP2003534359A (ja) 2003-11-18
CA2410025A1 (fr) 2001-12-06
ECSP024359A (es) 2004-03-23
CN100420439C (zh) 2008-09-24
BG65847B1 (bg) 2010-03-31
BRPI0111142B8 (pt) 2018-05-02
ATE300942T1 (de) 2005-08-15
EE05393B1 (et) 2011-04-15
BRPI0111142B1 (pt) 2017-10-24
NO20025635L (no) 2003-01-21
CN1635880A (zh) 2005-07-06
PT1283708E (pt) 2005-11-30
WO2001091696A8 (fr) 2003-01-09
HU229205B1 (en) 2013-09-30
ES2244625T3 (es) 2005-12-16
SK16582002A3 (sk) 2003-04-01
US7199159B2 (en) 2007-04-03
MXPA02011622A (es) 2003-03-27
AU6401101A (en) 2001-12-11
JP4987209B2 (ja) 2012-07-25
HUP0302038A2 (hu) 2003-09-29
BG107304A (bg) 2003-06-30
KR20030029050A (ko) 2003-04-11
AU2001264011B2 (en) 2005-09-15
EP1283708A2 (fr) 2003-02-19
DE60112431T2 (de) 2006-06-01
SK287249B6 (sk) 2010-04-07
WO2001091696A3 (fr) 2002-06-06
EP1283708B1 (fr) 2005-08-03
AR032617A1 (es) 2003-11-19
UA76415C2 (uk) 2006-08-15
DE60112431D1 (de) 2005-09-08
WO2001091696A2 (fr) 2001-12-06
HUP0302038A3 (en) 2009-08-28
US20030187036A1 (en) 2003-10-02
FR2809310B1 (fr) 2004-02-13
MY137468A (en) 2009-01-30
NO20025635D0 (no) 2002-11-22

Similar Documents

Publication Publication Date Title
BR0111142A (pt) Utilização de derivados de biguanida ou de seus sais farmaceuticamente aceitáveis
BR0316081A (pt) Derivados de 2-piridona como inibidores de elastase de neutrófilo
BR0311806A (pt) Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso
BR0210874A (pt) Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso
NO20021399L (no) Kazolinderivater og deres anvendelse som farmasöyter
BRPI0507818A (pt) composto e métodos de inibição
BR0205889A (pt) Pirazolopirimidinas como agentes tepapêuticos
BRPI0515885A (pt) derivados de ftalazinona, sua preparação e uso como agentes farmacêuticos
BRPI0413469A (pt) derivados de piperazina para o tratamento de infecções por hiv
BRPI0213522C1 (pt) compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto
BR0205890A (pt) Pirazolopirimidinas como agentes terapêuticos
BR0111263A (pt) Derivados de 2-aminocarbonil-9h-purina
BRPI0410714B8 (pt) derivados de quinazolina macrocíclicos, seu processo de preparação, composição farmacêutica que os compreende e uso
BRPI0804091B8 (pt) compostos de 1,2,4,5-tetrahidro-3h-benzazepina, processo para sua preparação e composições farmacêuticas que os contêm
BRPI0408437A (pt) derivados de p-diaminobenzeno substituìdos, composição farmacêutica, e, uso da mesma
BRPI0008753B8 (pt) composto de amida, processo para preparar um composto de amida, composição farmacêutica e uso de um composto de amida
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
BRPI0409465A (pt) derivados de carboxamida como agentes antidiabéticos
BR0212069A (pt) Agentes antidiabéticos orais
AR025103A1 (es) Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos
BR0111976A (pt) Preparação terapêutica para neurose ou depressão por ansiedade, e, derivado de piperazina
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0308162A (pt) Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
BR0214937A (pt) Processo de preparação de derivados de equinocandina
BR0111933A (pt) Uso de ácido pamÈico ou um de seus derivados, ou um de seus análogos, para a preparação de um medicamento para o tratamento de doenças caracterizadas por depósitos de agregados amilõides

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/05/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21I Extinguishment of a patent or of a certificate of addition of invention: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2672 DE 22/03/2022 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2675 DE 12/04/2022 POR TER SIDO INDEVIDA.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 23/05/2021